Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 1,653 · FY2023 1,050 · FY2024 1,880 — 3-yr total 4,583
Medinservi (სს კომპანია მედინსერვი) — a mid-size Georgian pharmaceutical importer/distributor (joint-stock company, ~196 employees). Revenue ~GEL 16–19m through 2017–2022, tapering toward 2024; ranked among Georgia's top-10 pharmaceutical importers (ranked ~9th by import value in 2010). A wholesale/import distributor, not a retail pharmacy.
Group parent — controls 2 companies · ownership
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash from Operating Activities | 1,550 | 1,134 | 1,496 | 999 | 2,472 | 5,257 | 1,715 | 3,844 | +13.9% |
| Net Cash used in Investing Activities | 0 | 193 | 30 | 128 | 27 | 299 | 1,238 | 216 | +1.9% |
| Free Cash Flow (OCF − Capex proxy) | 1,550 | 940 | 1,465 | 870 | 2,445 | 4,958 | 477 | 3,628 | +12.9% |
| Net Cash from Financing Activities | 0 | 616 | 2,626 | 1,288 | 919 | 1,604 | 913 | 1,666 | +18.0% |
| Net Change in Cash (before FX) | 1,550 | 324 | 1,160 | 417 | 1,525 | 3,355 | 436 | 1,963 | +3.4% |
| Effect of FX on Cash | 0 | 100 | 214 | 349 | 224 | 592 | 0 | 0 | nmf |
| Net Change in Cash (incl. FX) | 1,550 | 425 | 946 | 68 | 1,301 | 2,763 | 436 | 1,963 | +3.4% |
| Cash at Beginning of Year | 0 | 3,695 | 4,120 | 3,174 | 3,106 | 4,407 | 7,170 | 6,734 | +10.5% |
| Cash at End of Year | 0 | 4,120 | 3,174 | 3,106 | 4,407 | 7,170 | 6,734 | 8,697 | +13.3% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.